

## **EAQ211**



## For AYA Survivors of Hodgkin/Non-Hodgkin Lymphoma

## **EAQ211** Available Through ECOG-ACRIN Cancer Research Group

Social Genomic Mechanisms of Health Disparities among Adolescent and Young Adult (AYA) Survivors of Hodgkin and Non-Hodgkin Lymphoma

### **Patient Population**

See Section 3 for Complete Eligibility Details

Selection of Sites: NCORP sites

#### Selection of Participants:

- Must be ≥ 18 years of age at the time of registration
- Must have been between the ages of 15-39 at the time of their first primary cancer diagnosis of Hodgkin or Non-Hodgkin lymphoma
- Must have completed therapy (with a complete response, per clinician determination) at the time of registration
- Patient's last date of prior systemic therapy for first primary diagnosis for Hodgkin/Non-Hodgkin lymphoma must have been within I year prior to registration
  - Systemic therapy refers to all anti-cancer therapy, including but not limited to chemotherapy, IV/oral targeted medications, or radiation, and administered via a clinical trial or standard approach
- Must have an ECOG PS 0-3
- Must be English speaking (note: sites cannot translate the associated QOL forms)
- Must not be receiving active therapy for Hodgkin/Non -Hodgkin lymphoma
- Must have internet access through a computer, tablet, or smartphone
- Must have an email address

## **Methodology Plan**

See Section 5 for Methodology Details

- This is a longitudinal study of 2,000 AYA lymphoma survivors recruited within I year following completion of treatment for Hodgkin/Non-Hodgkin lymphoma
- Blood specimens will be collected at baseline and subsequently every 6 months over 2 years (at 6, 12, 18, and 24 months; +/- 14 days)
- Patient-reported outcome measures will be administered via online/mobile survey at the same time points (at 6, 12, 18 and 24 months; +/- 14 days)
  - ♦ Information from survey data will be captured via EASEE-PRO
  - Health-Related QOL (including physical wellbeing) will be assessed via the PROMIS-29 v2
  - Symptoms and late effects will be assessed via the self-administered Charlson Co-morbidity index and the NCI Common Toxicity Criteria for AEs
  - Social-environmental risk factors will be assessed by:
    - The Accountable Health Communities Health-Related Social Needs Screening Tool
    - The Attachment Subscale of the Social Provisions Scale
    - The Behavioral Risk Factor Surveillance System Adverse Childhood Experiences module
    - The Perceived Discrimination Scale
  - ♦ <u>Individual resilience factors</u> will be assessed by:
    - DUFSS
    - Mental Health Continuum Short Form
    - PROMIS Short Form
    - Indicators of socioeconomic status, assets, and employment/school status will be collected via survey

#### **Study Chair:**

Bradley J. Zebrack, PhD

Study Co-Chair: Steven Cole, PhD

### **Patient Enrollment**

All Sites: Oncology Patient Enrollment Network (OPEN) <a href="https://open.ctsu.org/open">https://open.ctsu.org/open</a>

#### **Protocol Information**

ECOG-ACRIN Operations-Boston: 857-504-2900, <a href="http://ecog-acrin.org">http://ecog-acrin.org</a> (Member Login)

Please Enroll Your Eligible Patients!

# EAQ211

